Evidence map›Paper›PMID 38463041›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Toward the right treatment at the right time: Modeling the trajectory of cognitive decline to identify the earliest age of change in people with Alzheimer's disease.

R Asaad Baksh, André Strydom, Ben Carter, Isabelle Carriere, Karen Ritchie

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

R Asaad BakshDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience King's College London Denmark Hill London UK.ORCID https://orcid.org/0000-0001-6596-2145
André StrydomDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience King's College London Denmark Hill London UK.
Ben CarterDepartment of Biostatistics and Health Informatics Institute of Psychiatry, Psychology and Neuroscience King's College London London UK.
Isabelle CarriereINSERM, Institut de Neurosciences de Montpellier INM Montpellier France.
Karen RitchieINSERM, Institut de Neurosciences de Montpellier INM Montpellier France.

Funding

Medical Research Council MR/R024901/1Medical Research Council MR/S011277/1
6 · The paper itself

Abstract

Introduction: Age is the greatest risk factor for Alzheimer's disease (AD). A limitation of randomized control trials in AD is a lack of specificity in the age ranges of participants who are enrolled in studies of disease-modifying therapies. We aimed to apply Emax (i.e., maximum effect) modeling as a novel approach to identity ideal treatment windows. Methods: Emax curves were fitted to longitudinal cognitive data of 101 participants with AD and 1392 healthy controls. We included the Mini-Mental State Examination (MMSE) and tests of verbal fluency and executive functioning. Results: In people with AD, the earliest decline in the MMSE could be detected in the 67-71 age band while verbal fluency declined from the 41-45 age band. In healthy controls, changes in cognition showed a later trajectory of decline. Discussion: Emax modeling could be used to design more efficient trials which has implications for randomized control trials targeting the earlier stages of AD.

Identifiers

PMID38463041
PMCPMC10921067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.